Company
Official Name: Novo Nordisk A/S
Headquarters: Bagsvaerd, Denmark
Founded: December 21, 1923
Employees: 47,792
CEO: Mr. Lars Fruergaard Jorgensen
kr.1.012 Trillion
DKK as of Jan. 1, 2026
US$158.96 Billion
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
| Company | Market Cap (USD) |
|---|---|
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Samsung Biologics Co.,Ltd. | $54.01 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B
Stock: FSX: NOVC
Stock: XETR: NOVC
Stock: XETR: NOVA
Stock: FSX: NOVA
Stock: BMV: NVON
Stock: NYSE: NVO
Stock: Bovespa: N1VO34
Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda
Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO)